Lianhe Xiaozhi ointment ameliorates metabolic dysfunction-associated steatotic liver disease via peroxisome proliferator-activated receptor alpha pathway activation

doi:10.3748/wjg.v32.i9.114544

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 9

This Article

(42)

(39)

(0)

(15)

(1)

(980)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Mar 7, 2026; 32(9): 114544
Published online Mar 7, 2026. doi: 10.3748/wjg.v32.i9.114544

Full Size Figure Download Figure

Figure 9 Proposed Lianhe Xiaozhi ointment mechanism in metabolic dysfunction-associated steatotic liver disease treatment. Solid black arrows signify promotional effects. Inverted blue arrows denote a reduction in content or activity, and the T-shaped solid line without an arrow represents inhibitory effects. LXO: Lianhe Xiaozhi ointment; PPAR: Peroxisome proliferator-activated receptor; CPT1A: Carnitine palmitoyl transferase 1a; NEFA: Non-esterified fatty acid; TG: Triglyceride; IL: Interleukin; NF-κB: Nuclear factor kappa-B; Acox1: Acyl-CoA oxidase 1; HMGCS2: 3-hydroxy-3-methylglutaryl-CoA synthase 2.

Citation: Nie LJ, Wang GX, Yang XY, Sun J, Cao YT, Lou Y, Lu YF, Yu JY, Zhou XQ. Lianhe Xiaozhi ointment ameliorates metabolic dysfunction-associated steatotic liver disease via peroxisome proliferator-activated receptor alpha pathway activation. World J Gastroenterol 2026; 32(9): 114544
URL: https://www.wjgnet.com/1007-9327/full/v32/i9/114544.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i9.114544

Nie LJ, Wang GX, Yang XY, Sun J, Cao YT, Lou Y, Lu YF, Yu JY, Zhou XQ. Lianhe Xiaozhi ointment ameliorates metabolic dysfunction-associated steatotic liver disease via peroxisome proliferator-activated receptor alpha pathway activation. World J Gastroenterol 2026; 32(9): 114544 [PMID: 41810443 DOI: 10.3748/wjg.v32.i9.114544]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.